Bristol Myers Squibb (CELG-RI) Change in Acquisitions & Divestments (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Change in Acquisitions & Divestments for 18 consecutive years, with $573.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments rose 9.35% year-over-year to $573.0 million; the TTM figure through Jun 2026 stood at $2.2 billion (up 110.25% YoY), while the FY2025 annual figure was $2.0 billion, up 76.02% from the prior year.
• Change in Acquisitions & Divestments improved to $573.0 million in Q2 2026 per CELG-RI's latest filing, from $391.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $2.1 billion in Q1 2022 and bottomed at $41.0 million in Q4 2023.
• Historically, Change in Acquisitions & Divestments has averaged $622.5 million across 5 years, with a median of $396.5 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments sank 97.05% — and 2024, when it soared 1104.84%.
• Bristol Myers Squibb's Change in Acquisitions & Divestments stood at $1.2 billion in 2022, then slumped by 96.6% to $41.0 million in 2023, then surged by 51.22% to $62.0 million in 2024, then soared by 548.39% to $402.0 million in 2025, then jumped by 42.54% to $573.0 million in 2026.
• Business Quant data shows CELG-RI's Change in Acquisitions & Divestments at $573.0 million in Q2 2026, $391.0 million in Q1 2026, and $402.0 million in Q4 2025.